{
    "root": "34271dec-082b-54e8-e063-6294a90a07a7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin",
    "value": "20250502",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        }
    ],
    "indications": "adults pediatric patients upper respiratory tract infections ear , nose , throat : amoxicillin capsules indicated treatment infections due susceptible ( β- lactamase–negative ) isolates streptococcusspecies . ( α- β-hemolytic isolates ) , streptococcus pneumoniae , staphylococcusspp . , haemophilus influenzae . infections genitourinary tract : amoxicillin capsules indicated treatment infections due susceptible ( β-lactamase–negative ) isolates escherichia coli , proteus mirabilis , enterococcus faecalis . infections skin skin structure : amoxicillin capsules indicated treatment infections due susceptible ( β-lactamase–negative ) isolates streptococcusspp . ( α- β-hemolytic isolates ) , staphylococcusspp . , e. coli . infections lower respiratory tract : amoxicillin capsules indicated treatment infections due susceptible ( β-lactamase–negative ) isolates streptococcusspp . ( α- β-hemolytic isolates ) , s. pneumoniae , staphylococcusspp . , h. influenzae . adult patients helicobacter pylori infection duodenal ulcer disease : triple therapy helicobacter pylori ( h. pylori ) clarithromycin lansoprazole : amoxicillin capsules combination clarithromycin plus lansoprazole triple therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) eradicate h. pylori . eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . dual therapy h. pyloriwith lansoprazole : amoxicillin capsules , combination lansoprazole delayed-release capsules dual therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) either allergic intolerant clarithromycin resistance clarithromycin known suspected . ( clarithromycin package insert , microbiology . ) eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin capsules antibacterial drugs , amoxicillin capsules used treat infections proven strongly suspected caused bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "adults , 750 1750 mg/day divided doses every 8 12 hours . pediatric patients 3 months age , 20 45 mg/kg/day divided doses every 8 12 hours . refer full prescribing information dosing regimens . ( 2.2 , 2.3 ) upper dose neonates infants aged 3 months younger 30 mg/kg/day divided every 12 hours . ( 2.3 ) dosing h. pylori infection ( adults ) : triple therapy : 1 gram amoxicillin , 500 mg clarithromycin , 30 mg lansoprazole , given twice daily ( every 12 hours ) 14 days . dual therapy : 1 gram amoxicillin 30 mg lansoprazole , given three times daily ( every 8 hours ) 14 days . ( 2.4 ) reduce dose patients severe renal impairment ( gfr greater 30 ml/min ) . ( 2.5 )",
    "warningsAndPrecautions": "amoxicillin capsules , usp contains 500 mg amoxicillin usp trihydrate . 500 mg capsule blue/pink size “ 0el ” hard gelatin capsule filled white white granular powder imprinted “ a45 ” pink body black ink . ndc : 70518-0895-00 ndc : 70518-0895-01 ndc : 70518-0895-02 ndc : 70518-0895-03 ndc : 70518-0895-04 ndc : 70518-0895-05 ndc : 70518-0895-06 ndc : 70518-0895-07 ndc : 70518-0895-08 ndc : 70518-0895-09 packaging : 30 1 bottle , type 0 packaging : 100 1 box packaging : 1 1 pouch packaging : 21 1 bottle plastic packaging : 21 1 bottle plastic packaging : 30 1 blister pack packaging : 21 1 blister pack packaging : 28 1 blister pack packaging : 30 1 bottle plastic packaging : 20 1 bottle plastic store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "amoxicillin capsules contraindicated patients experienced serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin capsules β-lactam antibacterial drugs ( e.g . , penicillins cephalosporins ) .",
    "indications_original": "Adults and Pediatric Patients\n                  \n                  \n                  \n                     \n                        Upper Respiratory Tract Infections of the Ear, Nose, and Throat:  Amoxicillin capsules\n  \n    are indicated in the treatment of infections due to susceptible (ONLY β- lactamase–negative) isolates of\n  \n   Streptococcusspecies. (α- and β-hemolytic isolates only),\n  \n   Streptococcus pneumoniae,\n  \n   Staphylococcusspp., or\n  \n   Haemophilus influenzae.\n \n  \n                  \n                  \n                  \n                     \n                        Infections of the Genitourinary Tract:Amoxicillin capsules\n  \n    are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n  \n   Escherichia coli, Proteus mirabilis, or\n  \n   Enterococcus faecalis.\n \n  \n                  \n                  \n                     \n                        Infections of the Skin and Skin Structure:\n                         Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n  \n   Streptococcusspp. (α- and β-hemolytic isolates only),\n  \n   Staphylococcusspp., or\n  \n   E. coli.\n \n  \n                  \n                  \n                     \n                        Infections of the Lower Respiratory Tract:\n                         Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n  \n   Streptococcusspp. (α- and β-hemolytic isolates only),\n  \n   S. pneumoniae, Staphylococcusspp., or\n  \n   H. influenzae.\n \n  \n                  \n                  \n                  \n                     Adult Patients only\n                  \n                  \n                  \n                     \n                        \n                           Helicobacter pylori\n                        \n                        Infection \n  \n   and Duodenal Ulcer Disease:\n                     \n                  \n                  \n                  \n                     Triple therapy for\n  \n   Helicobacter pylori (H. pylori)with clarithromycin and lansoprazole\n \n  :\n\n \n                  \n                  Amoxicillin capsules in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with\n \n  H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate\n \n  H. pylori. Eradication of\n \n  H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.\n\n \n                  \n                  \n                     Dual therapy for\n  \n   H. pyloriwith lansoprazole\n \n  : Amoxicillin capsules, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with\n \n  H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer)\n \n  who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of\n \n  H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.\n\n \n                  \n                  \n                     Usage\n                      \n                  \n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "In Adults, 750 to 1750 mg/day in divided doses every 8 to 12 hours. In Pediatric Patients over 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to 12 hours. Refer to full prescribing information for specific dosing regimens. ( 2.2 , 2.3 ) The upper dose for neonates and infants aged 3 months or younger is 30 mg/kg/day divided every 12 hours. ( 2.3 ) Dosing for H. pylori Infection (in Adults): Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. ( 2.4 ) Reduce the dose in patients with severe renal impairment (GFR greater than 30 mL/min). (2.5)",
    "warningsAndPrecautions_original": "Amoxicillin Capsules, USP contains 500 mg amoxicillin USP as the trihydrate.\n                  500 mg Capsule\n                  \n                  Blue/Pink size “0EL” hard gelatin capsule filled with white to off white granular powder and imprinted with “A45” on pink body with black ink.\n                  NDC: 70518-0895-00\n                  NDC: 70518-0895-01\n                  NDC: 70518-0895-02\n                  NDC: 70518-0895-03\n                  NDC: 70518-0895-04\n                  NDC: 70518-0895-05\n                  NDC: 70518-0895-06\n                  NDC: 70518-0895-07\n                  NDC: 70518-0895-08\n                  NDC: 70518-0895-09\n                  PACKAGING: 30 in 1 BOTTLE, TYPE 0\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 21 in 1 BOTTLE PLASTIC\n                  PACKAGING: 21 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 21 in 1 BLISTER PACK\n                  PACKAGING: 28 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  \n                  Store at  20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight container.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Amoxicillin capsules are  contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin capsules or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins)."
}